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Antibiotics are important adjuncts in the treatment of infectious diseases, including periodontitis. The most severe criticisms to the indiscriminate use of these drugs are 
their side effects and, especially, the development of bacterial resistance. The knowledge 
of the biological mechanisms involved with the antibiotic usage would help the medical and 
dental communities to overcome these two problems. Therefore, the aim of this manuscript 
was to review the mechanisms of action of the antibiotics most commonly used in the 
periodontal treatment (i.e. penicillin, tetracycline, macrolide and metronidazole) and the 
main mechanisms of bacterial resistance to these drugs. Antimicrobial resistance can be 
classified into three groups: intrinsic, mutational and acquired. Penicillin, tetracycline and 
erythromycin are broad-spectrum drugs, effective against gram-positive and gram-negative 
microorganisms. Bacterial resistance to penicillin may occur due to diminished permeability 
of the bacterial cell to the antibiotic; alteration of the penicillin-binding proteins, or 
production of β-lactamases. However, a very small proportion of the subgingival microbiota 
is resistant to penicillins. Bacteria become resistant to tetracyclines or macrolides by limiting 
their access to the cell, by altering the ribosome in order to prevent effective binding of the 
drug, or by producing tetracycline/macrolide-inactivating enzymes. Periodontal pathogens 
may become resistant to these drugs. Finally, metronidazole can be considered a prodrug in 
the sense that it requires metabolic activation by strict anaerobe microorganisms. Acquired 
resistance to this drug has rarely been reported. Due to these low rates of resistance and 
to its high activity against the gram-negative anaerobic bacterial species, metronidazole 
is a promising drug for treating periodontal infections.
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INTRODUCTION
Antimicrobial agents are substances produced 
by various species of microorganisms (bacteria, 
fungi, actinomycetes) that suppress the growth of 
other microorganisms and may eventually destroy 
them. However, common usage often extends the 
term “antibiotics” to include synthetic or semi-
synthetic antibacterial agents, such as sulfonamides 
and metronidazole, which are not produced by 
microbes. The modern era of antimicrobial therapy 
started with the clinical use of sulfonamide in 
1936. The “golden age” of antibiotics began with 
the production of penicillin in 1941, when this 
compound, discovered by Alexander Fleming in 
1928, was finally mass-produced and first made 
available for limited clinical trials18. The remarkable 
success of penicillin in treating bacterial infections 
quickly diverted a great deal of scientific effort 
towards the search for other antibiotics. Different 
laboratories initiated an intensive search for 
antibiotics produced by moulds isolated from soil 
samples from all parts of the world and further 
successes quickly followed. Since then, hundreds 
of antibiotics have been identified, and many have 
been developed to the stage where they are of value 
in the therapy of numerous infections, including 
periodontal diseases.
Microbial resistance is a natural biological 
response of microbes to a selective pressure, 
such as weather conditions, food, oxygen or water 
availability, or the presence of an antimicrobial 
drug. When a new class of antibiotic is introduced, 
it is effective at first, but will eventually select for 
survival of the small fraction of bacterial populations 
that have an intrinsic or acquired resistance 
mechanism166. However, there is a scarcity of 
information on the susceptibility to antibiotics 
of bacterial species isolated from patients with 
periodontitis, since microbial sensitivity tests are 
not normally performed in daily practice either in 
dentistry or in medicine, especially in countries 
where there is high antibiotic consumption86. 
This habit has contributed to the emergence of 
multidrug-resistant strains of both Gram-negative 
(Pseudomonas, Klebsiella, Salmonella) and 
Gram-positive (Staphylococcus, Enterococcus, 
Streptococcus) species and has become a public 
health problem135.
The commensal microbiota of the oral cavity 
can act as a reservoir of antibiotic-resistant 
microorganisms, some of which are capable of 
causing local and systemic diseases. Data from 
the literature suggest that antibiotic resistance in 
the periodontal microbiota has increased163. The 
knowledge of the biological mechanisms involved 
with antibiotic usage as well as of the results of 
well conducted randomized clinical trials would 
help dental professionals prescribing these drugs 
only when their real efficacy for the treatment of 
a certain infection has been proved. This is the 
most effective way of avoiding the development of 
resistance. Therefore, the aim of this manuscript 
was to review the mechanisms of action of the 
antibiotics most commonly used in the periodontal 
treatment (i.e. penicillin, tetracycline, macrolide 
and metronidazole), and the main mechanisms of 
bacterial resistance to these drugs.
MEChANISM OF ACTION AND 
RESISTANCE
I- general considerations
One of the results of the widespread use of 
antibiotics has been the emergence of antibiotic-
resistant pathogens, a phenomenon that constitutes 
a threat to the successful treatment of infectious 
diseases. To understand the mechanisms of 
resistance it is important to remind that antibiotics 
are classified based on their mechanism of action, 
as follows:
Agents that inhibit synthesis of bacterial cell 
walls (e.g. penicillins and cephalosporins);
Agents that interfere with the cell membrane 
of the microorganism, affecting permeability ( e.g. 
some antifungal agents);
Agents that inhibit protein synthesis by affecting 
the function of 30S or 50S ribosomal subunits (e.g. 
tetracyclines, macrolides and clindamycin);
Agents that block important metabolic steps 
of the microorganisms (e.g. sulfonamides and 
trimethoprim);
Agents that interfere with nucleic acid synthesis 
(e.g. metronidazole and quinolones).
Antimicrobial resistance can be classified 
into 3 groups: intrinsic, mutational and acquired 
resistance. Intrinsic resistance refers to an inherent 
resistance to an antibiotic that is a naturally occurring 
feature of the microorganism. For example, certain 
oral bacteria such as many streptococci lack the 
nitroreductases necessary to convert metronidazole 
to its active metabolites and therefore are not 
affected by the drug163. Mutational resistance occurs 
due to a spontaneous chromosomal mutation that 
produces a genetically-altered bacterial population 
that is resistant to the drug. Mutations resulting 
from the change of a single nucleotide base can 
result in resistance, as has been well documented 
for aminoglycosides and for rifampin163. Finally, 
acquired resistance refers to the horizontal 
acquisition from another microorganism of a genetic 
element that encodes antibiotic resistance. This 
process can occur by transduction, transformation 
or conjugation. Transduction is a process by which 
exogenous DNA is transferred from one bacterium 
to another by the intervention of a bacteriophage, 
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while transformation is the process by which 
bacteria acquire segments of DNA that are free 
in the environment. In conjugation the passage 
of genetic material occurs by direct cell-to-cell 
contact, through a sex pilus or bridge. This is the 
most common mechanism of transferring antibiotic 
resistance genes.
In general, bacteria use 3 main strategies 
to become resistant to different antibiotics: (a) 
preventing the drug from reaching its target100,101, 
(b) altering the target62,145, and (c) inactivating the 
antibiotic28,124.
II- Penicillins
Penicillins, together with the cephalosporins, 
are the major β-lactam antibiotics. In 1928, while 
studying staphylococcus variants, Alexander 
Fleming observed that a mold contaminating one of 
his cultures caused the lyses of adjacent bacteria. 
Because the mold belonged to genus Penicillium, 
Fleming named the antibacterial substance 
penicillin. More than a decade later, in 1941, enough 
purified penicillin had been produced to conduct 
therapeutic trials in several patients desperately 
ill with staphylococcal and streptococcal infections 
and the results were exceptional. Since then, many 
other antimicrobial agents have been developed but 
the penicillins are still one of the most important 
groups of antibiotics and new derivatives of the 
basic penicillin nucleus are still being produced.
The basic structure of the penicillins consists 
of a thiazolidine ring connected to a β-lactam 
ring, to which is attached an acyl side chain. The 
first penicillin introduced, penicillin G, is the only 
natural penicillin currently used clinically. The 
first semi synthetic derivative, penicillin V, was 
found to be more stable than penicillin G following 
oral administration. However, both drugs have 
limited activity against Gram-negative bacteria 
and are readily hydrolyzed by bacterial-produced 
hydrolyzing enzymes, β-lactamases. Later, further 
modifications and substitutions of the acyl side 
chain, led to the production of other semi synthetic 
penicillins with enhanced antimicrobial properties. 
Such properties included activity against Gram-
negative as well as Gram-positive bacteria with a 
narrow spectrum of activity directed against specific 
bacteria, increased stability in oral and stomach 
acids and increased absorption, resulting in lower 
dosages necessary to establish therapeutic levels164.
The penicillins as well as other β-lactam 
antibiotics are bactericidal drugs. They kill 
susceptible bacterial by inhibiting the synthesis 
of the bacterial peptidoglycan cell wall144,169. The 
peptidoglycan provides the cell with rigid stability 
due to its highly cross-linked structure and its 
synthesis has 3 stages. The first and second 
stages take place in the cytoplasm. Initially, there 
is amino sugar linkage followed by the addition 
of specific amino acids (L-alanine, D-glutamic 
acid, L-lysine, followed by a dipeptide, D-alanyl-
D-alanine) in a prescribed order to form uridine 
diphosphate (UDP)-acetylmuramyl-pentapeptide. 
The final stage occurs outside the cell to complete 
the cross-link, when new subunits are added to the 
growing peptidoglycan. The terminal glycine residue 
of the pentaglycine bridge is linked to the fourth 
residue of the pentapeptide (D-alanine), releasing 
the fifth residue (also D-alanine)87. The penicillins 
and cephalosporins interfere with this last step in 
peptidoglycan synthesis by acting as an analog of 
the D-alanine-D-alanine portion of the N-acetyl 
muramic moiety. The conformation of penicillin is 
very similar to that of D-alanine-D-alanine, so the 
enzymes involved in the transpeptidation reaction 
react with the β-lactam nucleus, inactivating the 
transpeptidase reaction and results in the formation 
of new peptidoglycan chains that are not cross-
linked and lack tensile strength. Weak points 
develop in the growing cell wall, which result in cell 
rupture due to osmotic lysis169. In addition, there 
are more targets for the actions of penicillins, which 
are collectively termed penicillin-binding proteins 
(PBP)143, structures that all bacteria possess. 
Resistance to penicillin may occur due to any 
of the 3 mechanisms described in the introduction 
section:
a) Preventing the drug from reaching its target: 
diminished permeability of the bacterial cell to the 
antibiotic;
b) Altering the target: alteration(s) of the 
penicillin-binding proteins;
c) Inactivating the antibiotic: bacterial 
production of inactivating enzymes, referred to as 
β-lactamases.
IIa- Diminished permeability of the bacterial 
cell to the antibiotic
This type of resistance is only observed in 
Gram-negative organisms due to differences found 
in the structure and composition of Gram-positive 
and Gram-negative cell wall. In Gram-positive 
bacteria the peptydoglycan polymer is very close 
to the cell surface, allowing the antibiotic to easily 
penetrate the cell. The situation is different with 
Gram-negative bacteria, since they contain an outer 
membrane consisting of lipopolysaccharide that acts 
as a barrier to hydrophobic compounds in general, 
and to hydrophilic compounds that exceed a certain 
molecular weight. The outer membrane functions 
as an impenetrable barrier to some antibiotics98. 
However, some small, hydrophilic antibiotics diffuse 
through aqueous channels in the outer membrane 
formed by proteins called porins. This is the 
primary reason for the difference in susceptibility 
of Gram-negative and Gram-positive bacteria to 
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hydrophobic antibiotics such as certain penicillins. 
Broader spectrum penicillins, such as ampicillin 
and amoxicillin, diffuse through the porin pores of 
Gram-negative bacteria significantly more rapidly 
than penicillin G. The number and size of pores in 
the outer membrane are variable among different 
Gram-negative bacteria. For example, Haemophilus 
influenzae is thought to be much more susceptible 
to β-lactam antibiotics than Escherichia coli due to 
the presence of larger porin channels156. Specific 
mutations of gene(s) coding for the porin proteins 
can impair the entry of hydrophobic penicillins into 
the cell and result in an increase in the minimal 
inhibitory concentration of the antibiotic for the 
organism163.
IIb- Alteration(s) of the penicillin-binding 
proteins
Microorganisms may be intrinsically resistant 
to penicillin because of structural difference in the 
PBPs that are the targets of this drug. It is also 
possible that a sensitive strain acquires resistance 
of this type by altering the PBP affinity to β-lactam 
antibiotics, as observed in methicillin-resistant 
staphylococci48 and in penicillin-resistant gonococcal 
strains60. It has also been reported that the high-
level of resistance of Streptococcus pneumoniae 
to β-lactam antibiotics is mediated by successive 
alterations in essential PBPs. These low affinity PBPs 
may be a result to an acquired mutation or bee due 
to interspecies gene transfer54.
IIc- Bacterial production of β-lactamases
The most important mechanism of resistance 
to penicillins and cephalosporins is β-lactamase 
mediated hydrolysis of the β-lactam ring, resulting 
in inactivation of the antibiotic. These enzymes are 
often referred to as penicillinase or cephalosporinase, 
depending on the drug on which they act. However, 
some enzymes demonstrate activity against both 
classes of antibiotics. In general, Gram-positive 
bacteria produce a large amount of β-lactamase, 
which is secreted extracellularly. Therefore, in a 
mixed bacterial population, such as the subgingival 
microbiota of a periodontal pocket, the production of 
β-lactamase by relatively few Gram-positive bacteria 
may protect other bacteria that would normally 
be susceptible to penicillins. In Gram-negative 
bacteria, β-lactamases are found in relatively small 
amounts and are located in the periplasmic space, 
between the inner and outer cell membranes. 
Since the enzymes of cell-wall synthesis are on the 
outer surface membrane, these β-lactamases are 
strategically located for maximal protection of the 
microbe. Therefore, the production of a relatively 
small amount of β-lactamase that is retained within 
the outer membrane of Gram-negative bacteria is 
often sufficient to keep the internal concentration of 
the antibiotic below inhibitory levels. β-lactamases 
can be either chromosomal or plasmid encoded, and 
they may be constitutive or inducible.
IId- Resistance of oral species
A very small proportion of the subgingival 
microbiota is resistant to penicillins69,114,150. Suter, 
et al.150 (1983) reported that among 193 assorted 
oral isolates, only 2% were resistant to penicillin G 
at a concentration of 2 U/mL. Kinder, et al.69 (1986) 
also showed that less than 3% of the subgingival 
microorganisms associated with adult periodontitis 
were resistant to penicillin. The predominant 
resistant subgingival isolates recovered in this 
investigation consisted of Bacteroides, Veillonella, 
Haemophilus, Eikenella, Capnocytophaga, and 
Streptococcus species73,149,150. The main mechanism 
of resistance to β-lactam antibiotics in the oral 
cavity seems to be the production of β-lactamase. 
This enzyme is frequently detected in diseased 
periodontal sites and appears to be positively 
correlated with increased periodontal pocket 
depth165. β-lactamases have been detected in 
dark-pigmented Prevotella species, Haemophilus 
and Capnocytophaga species in patients with 
adult periodontitis70. Van Winkelhoff, et al.161 
(1997) determined the occurrence of β-lactamase 
producing periodontal bacteria in 23 untreated 
adult periodontitis patients. Of the selected 
putative periodontal species, strains of Prevotella 
intermedia, Fusobacterium nucleatum and to the 
first time, Tannerella forsythia, were β-lactamase 
positive, with P. intermedia being the most 
frequently detected enzyme positive species. 
Feres, et al.36 (2002) analyzed the microbiota in 
20 subjects with chronic periodontitis assigned 
to receive orally administered amoxicillin at the 
dosage of 500 mg, T.I.D. for 14 days. In order to 
determine the antibiotic resistance, subgingival 
plaque samples were taken from six posterior teeth 
at baseline and at 90 days; and from two randomly 
selected teeth at 3, 7 and 14 days during and 
after antibiotic administration. The most prevalent 
resistant species were S. constellatus, Prevotella 
nigrescens, Eubacterium saburreum, Actinomyces 
naeslundii 1, S. oralis, Prevotella melaninogenica 
and P. intermedia; however, the mean percentage 
of resistant isolates increased during antibiotic 
administration and returned to baseline levels 
by 90 days post-therapy. Handal, et al.55 (2004) 
demonstrated a wide variety and a high prevalence 
(72%) of β-lactamase-producing bacteria that may 
play a role in refractory periodontal disease. Species 
belonged to genus Prevotella and other anaerobic 
strains such as F. nucleatum, Capnocytophaga spp. 
and Neisseria sp. were also detected among these 
enzyme producers.
The prevalence of β-lactamase producers 
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seems to increase with age. Nyfors, et al.103 (2003) 
selected healthy 2-month-old infants for a 22-month 
longitudinal study. They found a prevalence of F. 
nucleatum of 2% and 49% at baseline and the end 
of the study, respectively. Most of the β-lactamase-
producing isolates (80%) were clearly resistant to 
penicillin G. Also, among 35 children (4-5 years 
old), Ready, et al.114 (2003) found many strains 
of the genus Veillonella, traditionally susceptible 
to penicillin and ampicillin, resistant to both 
antimicrobials.
Inhibitors of β-lactamase such as clavulanic 
acid can be combined with amoxicillin, for 
instance, resulting in a β-lactamase resistant drug 
concentration53,88. This combination has shown 
beneficial effects on the treatment of chronic 
and refractory periodontitis from 10 months to 
3 years post-treatment26,49,50,88 . Chan and Chan19 
(2003) assessed 178 bacterial strains isolated 
from 74 patients (9-72 years old) with pyogenic 
infections of odontogenic origin. When comparing 
the bactericidal activity, amoxicillin/clavulanate was 
more effective than amoxicillin alone in susceptible 
strains of P. intermedia, P. micra and Eikenella 
corrodens. Both the MIC50 and MIC90 of amoxicillin/
clavulanate were 2 to 4 times lower than those of 
amoxicillin and ampicillin, respectively, but there 
were some strains of E. corrodens (8,4%), F. 
nucleatum (11,4%)  and P. micra (11,1%) that 
were resistant to amoxicillin/clavulanate.
In addit ion to periodontal pathogens, 
opportunistic or superinfectant microorganism 
have also been detected in oral samples as 
Enterococcus faecalis and Staphylococcus aureus. 
E. faecalis were identified in 11% of oral rinses 
from endodontic patients and all strains were 
susceptible to ampicillin131. Loberto, et al.83 (2004) 
isolated Staphylococcus aureus from 4.55% of the 
subgingival samples of 88 patients with chronic 
periodontitis. Bernardo, et al.9 (2005) reported a 
high percentage (79.5%) of S. aureus resistant 
to ampicillin in the dental clinic environment, 
which may represent a risk to patients if cross-
contamination occurs. As mentioned before, 
a resistant bacterial species may transfer the 
resistance genes to other oral bacterial species, 
especially in a biofilm environment.
III- Tetracyclines
After intensive screening of soil specimens 
collected from many parts of the world for antibiotic 
producing organisms, the first tetracycline, 
chlortetracycline was introduced in 194868. 
Subsequently, thousands of related compounds 
have been examined, a few of which have been 
developed for clinical use to treat infectious 
diseases.
Although there are specific differences between 
the currently available tetracyclines, they are 
sufficiently similar to allow them to be discussed as a 
group. They are broad-spectrum antibiotics effective 
against aerobic and anaerobic Gram-positive and 
Gram-negative bacteria as well as Richettsia, 
Mycoplasma, Chlamydia spp. and Legionella spp. 
They consist of 4 fused cyclic rings, hence the 
name tratracyclines. The various derivatives have 
only minor alterations of the chemical constituents 
attached to this basic ring structure164. The most 
commonly used are tetracycline hydrochloride, 
doxycycline and minocycline. All three have a 
similar spectrum of activity, and resistance to one 
may indicate resistance to all three. Tetracyclines 
are bacteriostatic agents at clinically achieved 
concentrations130. They inhibit bacterial protein 
synthesis by binding to the 30S bacterial ribosome 
and preventing access of aminoacyl tRNA to 
the acceptor (A) site on the mRNA-ribosome 
complex90,148. This interrupts the formation of 
the initiation complex required for amino acid 
protein synthesis29. Tetracyclines can also cause 
alterations in the cytoplasmic membrane leading 
to leakage of nucleotides and other compounds 
from the bacterial cell109. At higher concentrations, 
tetracycline may inhibit protein synthesis in 
mammalian cells. However, mammalian cells lack 
the active transport system found in bacteria that 
pump tetracyclines through the inner cytoplasmic 
membrane. Furthermore, differences in sensitivity 
at the ribosomal level are important determinants 
of the selective action of these drugs68. Doxycycline 
and minocycline are semi-synthetic derivatives of 
tetracycline. These two compounds are more lipid 
soluble which gives them some advantages over 
tetracycline hydrochloride, such as a lower dosage 
regimen, prolonged serum half-life, super tissue-
fluid penetration and decreased gastrointestinal 
side-effects8,21. In addition to the antimicrobial 
effect, tetracyclines are capable of inhibiting 
collagenase40. This inhibition may interfere 
with tissue breakdown in periodontal disease. 
Furthermore they bind to tooth surfaces, from 
which they may be released slowly over time146. 
Bacteria use 3 strategies to become resistant to 
tetracycline: 41,118,142:
a) Preventing the drug from reaching its target: 
limiting the access of tetracycline to the ribosomes;
b) Altering the target: altering the ribosome to 
prevent effective binding of tetracycline;
c) Inactivating the antibiotic: producing 
tetracycline-inactivating enzymes.
IIIa. Limiting tetracycline access to the 
ribosome
Reduced uptake
For tetracycline to inhibit protein synthesis, 
it must enter the bacterial cell and bind to the 
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ribosome. Some Gram-negative bacteria limit 
the diffusion of tetracycline into the periplasm by 
altering the porin proteins (e.g. OmpF) present 
in the cell wall. This type of resistance, which can 
decrease susceptibility 6- to 18- fold, has been 
found in a number of Gram-negative bacteria24,25,128. 
Cohen, et al.25 (1988) have shown that the multiple 
antibiotic resistances of some E. coli strains are due 
not only to change in OmpF but also to changes in 
other outer membrane proteins.
 
Tetracycline efflux
A second way of limiting the access of tetracycline 
to ribosomes is to reduce intracellular concentrations 
of tetracycline by pumping the antibiotic out of the 
cell at a rate equal to or greater than its uptake142. 
This resistance mechanism, tetracycline efflux, 
is the best-studied and most familiar mechanism 
of bacterial resistance91. Two major groups of 
efflux systems are known, specific exporters and 
transporters conferring multidrug resistance. 
The genes of multidrug resistance systems are 
commonly located on the bacterial chromosome. 
In contrast, the genes coding for specific efflux 
systems are often associated with mobile genetic 
elements which can easily be interchanged between 
bacteria15. The resistance gene product is a 
cytoplasmic membrane protein that is an energy-
dependent tetracycline transporter. To date, many 
classes of tetracycline efflux genes have been 
identified. tet(A) to tet(e) were found among the 
members of the family of Enterobacteriaeceae and 
the genera Haemophilus, Vibrio, Aeromonas, and 
Moraxella80,122. tet(P), has been found in Clostridium 
spp1 and tet(K) and (L) were detected in Gram-
positive bacteria11,61,92. tet(G), (H), (V) and otrA 
were identified and also specify active efflux of 
tetracycline32,33,56,118. In 2000, Tauch, et al.153 (1979) 
propose a new class of tetracycline resistance and 
repressor proteins, termed TetA(Z) and TetR(Z). 
Furthermore, proteins of the TetR family have been 
found in 115 genera of Gram-positive, alpha, beta 
and gamma-proteobacteria, cyanobacteria and 
archaea113.
Efflux pumps can be considered potentially 
effective antibacterial targets. Inhibition of efflux 
pumps by an efflux pump inhibitor would restore 
the activity of an agent subject to efflux81. Moreover, 
according to Kaatz67 (2005) the identification of 
broad-spectrum efflux pump inhibitors may reduce 
the need to discover and develop new antimicrobial 
agents that are not pump substrates.
IIIb- Ribosome protection
This is a less familiar type of tetracycline 
resistance mechanism than the efflux type. Burdett, 
in 198614, was the first to show that the ribosomes 
of resistant cells were in fact less sensitive to 
tetracycline than those of sensitive cells in an in 
vitro translation system. Although this mechanism 
is less familiar, it is probably more widespread 
than tetracycline efflux126. The resistance gene 
product is a cytoplasmic protein that interacts or 
associates with the ribosome, making it insensitive 
to tetracycline13,14. In 1991, Burdett13 purified one of 
the ribosome protection resistance proteins (Tet(M)) 
and showed that it could bind the ribosomes. Some 
classes of the ribosome protection resistance 
genes have been characterized and sequenced: 
tet(M), tet(O), tet(Q) and tet(S)20,78,102,126. Tet(O) 
and Tet(M) (75% sequence similarity) are soluble 
cytoplasmic proteins located on mobile genetic 
elements27. Tet(M) has been found in a wide 
variety of bacteria, including Streptococcus, 
Neisseria, Haemophilus, Mycoplasma, Bacteroides 
and Staphylococcus31,66,99. Tet(O), originally found 
in Campylobacter spp., has also been found in 
Streptococcus, Enterococcus, Lactobacillus and 
Mobiluncus spp.119,171 while tet(Q) has been found 
in Bacteroides and Prevotella species75,102,107,108. 
Finally, during a investigation of anaerobic bacteria 
present in swine feces and manure storage pits 
Whittle, et al.167 (2003) isolated a new Bacteroides 
strain (Bacteroides sp. Strain 139) that contained a 
previously unidentified tetracycline resistance gene 
designated Tet(36).
IIIc- Tetracycline inactivation
The third type of tetracycline resistance 
mechanism is the enzymatic inactivation of the 
drug. This type of resistance was discovered 
by accident when Guiney, et al.47 (1989) were 
attempting to clone a tetracycline resistance gene 
from the obligate anaerobe Bacteroides fragilis. 
They cloned a gene that conferred tetracycline 
resistance on E. coli, but it did not confer resistance 
on the Bacteroides. This resistance gene has 
been classified as tet(X) and the gene product 
is a cytoplasmic protein that chemically modifies 
tetracycline in a reaction that requires oxygen142. 
The clinical significance of tet(X) is unclear. Not 
only does it not confer resistance to the Bacteroides 
strains in which it was originally found, but it 
requires such high levels of aeration to function as 
a resistance factor in E. coli that it probably could 
not confer meaningful levels of resistance in the 
microaerophilic environment found in most sites 
of the human body142.
IIId- Resistance of oral species
Resistance to tetracycline in periodontal 
pathogens has been observed. Fiehn and 
Westergaard37 (1990) examined the presence of 
doxycycline resistant bacteria in subgingival plaque 
of 12 periodontally healthy and 12 periodontally 
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diseased subjects. At baseline, the occurrence of 
bacteria resistant to 10 μg/mL of doxycycline was 
around 4% in the healthy group and 1% in the 
diseased group. The periodontally diseased subjects 
received conventional therapy supplemented by 
doxycycline at the dosage of 100 mg/day for 20 
days. The percentage of resistant bacteria increased 
from 1% to 18% within 1 week after starting the 
therapy. However, this change was transient, as 
about 6 months after therapy the values returned 
to baseline. A similar study was carried out by 
Olsvik, et al.106 (1995) in a group of patients with 
refractory periodontal disease. Bacterial isolates 
resistant to 10 μg/mL of tetracycline were isolated 
from plaque samples of 17 patients, of whom 6 
had received tetracycline within 8 weeks prior to 
sampling. In these 6 patients, a mean of 22.9% 
of the total cultivable subgingival microbiota 
was resistant to tetracycline, compared with a 
mean of 7.2% in the untreated group. Although 
various organisms were isolated, in the majority of 
patients, the tetracycline-resistant organisms were 
dominated by Streptococcus spp. Magnusson, et 
al.89 (1991) compared the patterns of susceptibility 
to 6 antimicrobial agents of whole plaque samples 
from 18 patients with refractory periodontitis 
and 10 patients with chronic periodontitis. The 
isolates from the group with refractory periodontitis 
showed a tendency to higher levels of antimicrobial 
resistance to a variety of drugs. This difference 
was significant for tetracycline and for doxycycline 
at 4 μg/ml. Chan and Chan19 (2003) assessed 178 
bacterial strains isolated from 74 patients (9-72 
years old) with pyogenic infections of odontogenic 
origin. Tetracycline exhibited poor activity against 
the oral pathogenic bacteria. Conversely, the new 
tetracycline derivates, minocycline and doxycycline 
with a breakpoint of 8 μl/mL, expresses very 
pronounced antimicrobial activity and could inhibit 
over 95% of the isolated species, including P. 
gingivalis, E. corrodens, P. intermedia, F. nucleatum 
and P. micra, at a MIC90.
Abu Fanas, et al.2 (1991) reported an increase 
in the MIC values of tetracycline for subgingival 
isolates of P. gingivalis, P. intermedia and F. 
nucleatum in a group of subjects that received 250 
mg tetracycline 4 times daily for 2 weeks. There 
is evidence that long-term use tetracycline favors 
the selection or development of resistant strains in 
periodontal pockets72,168. Kornman and Karl72 (1982) 
evaluated 10 patients with periodontal disease who 
had been taking 250 mg of tetracycline daily for 
2-7 years. They reported that up to 77% of the 
cultivable subgingival microbiota was resistant to 
tetracycline at 1 μg/ml and Gram-negative rods 
constituted 58% of the microbiota. Another 10 
patients who had received the same treatment were 
examined 6 months after discontinuing the long-
term antibiotic therapy and the resistant species 
dropped to 26%. In the same study, 14 untreated 
control subjects had a mean of 7% resistant 
isolates. Goodson and Tanner42 (1992) studied the 
antibiotic resistance of the subgingival microbiota 
in tetracycline fiber-treated periodontal sites. No 
Gram-negative rods resistant to tetracycline at 16 
μg/mL were observed six months after patients 
received the local treatment. Intermediate levels 
of tetracycline resistance before and after the 
fiber therapy were observed for E. corrodens, 
Campylobacter gracilis, P. oris. Capnocytophaga 
gingivalis and Selenomonas sp. In no case was 
resistance higher after therapy than before.
Rodrigues, et al.125 (2004) longitudinally 
evaluated the tetracycline resistance patterns of 
the subgingival microbiota of periodontitis subjects 
treated with systemic or local antibiotic plus 
scaling and root planing (SRP). The predominant 
tetracycline-resistant species included P. 
intermedia, Veillonela parvula, P. micra and A. 
actinomycetemcomitans6,30. The percentage of 
resistant microorganisms increased significantly 
in a time interval of 1 week in the tetracycline 
groups, but dropped to baseline levels over time. 
The authors concluded that local or systemically 
administered tetracyclines result in only a transitory 
selection of subgingival species intrinsically 
resistant to this drug.
Van Winkelhoff, et al.158 (2000) investigated 
antimicrobial resistance of the subgingival microbiota 
of untreated patients with chronic periodontitis in 
the Netherlands and Spain. The percentage of 
resistant strains of most periodontal pathogens was 
higher among Spanish patients. In Spain, 5 patients 
had at least 3 tetracycline resistant periodontal 
pathogens, whereas this was not observed in any 
of the Dutch patients.
Resistance to tetracycl ine among oral 
microorganisms has also been examined at the 
genetic level. The tet(M) determinant is commonly 
found in some subgingival species considered 
“beneficial” such as oral streptococci, Veillonella and 
Actinomyces spp.74,104,105,121. Lacroix and Walker74 
(1995) subcultured and identified 204 tetracycline-
resistant strains from 68 patients with chronic 
periodontitis. Tet(M) was detected in 60% of the 
isolates. The tet(M) containing strains consisted 
mainly of streptococci (55%, mostly S. intermedius, 
S. oralis, S. sanguinis), Actinomyces spp. (14%), 
Bifidobacterium spp. (11%) and Veillonella spp. 
(10%).
Of the periodontal pathogens, several strains of 
F. nucleatum have been shown to harbor the tet(M) 
determinant in a conjugal transposon120. More 
recently Olsvik, et al.105 (1995), using the polymerase 
chain reaction (PCR), reported the presence of the 
tet(M) gene in one isolate of E. saburreum and in 
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two isolates of Gemella morbillorum. A 519-base-
pair fragment of the tet(O) gene was also amplified 
from 13 streptococcal isolates.
The tet(Q) determinant confers resistance to 
tetracycline only in Gram-negative rods74,107,108. The 
gene was first detected in intestinal Bacteroides 
species47,137 but a closely related determinant has 
been found in some oral Prevotella species46,107. 
Afterwards, Olsvik, et al.104 (1996) and Lacroix 
and Walker75 (1996) encountered the tet(Q) 
gene in tetracycline resistant Prevotella isolates 
from periodontally diseased patients, including P. 
intermedia and P. nigrescens.
Villideu, et al.162 (2003) screened saliva and 
plaque samples of 20 healthy adults for the 
presence of bacteria resistant to tetracycline 
presenting tetracycline resistance genes. The 
most common tet gene identified was tet(M), 
followed by tet(W), tet(0) and tet(Q). The authors 
reported, for the first time, the isolation of tet(W) 
gene from the oral cavity. This gene was present 
in genus Veillonella, Prevotella, Spreptococcus, 
Staphylococcus, Lactobacillus and Neisseria. Kim, 
et al.69 (2011) analyzed resistance determinants 
in oral biofilm samples associated with periodontal 
health or disease. Interestingly, the levels of tet(Q), 
tet(M), and ermF were higher in samples from the 
periodontitis than from the periodontally healthy 
group. The authors emphasize that this may occur 
because some of these resistant genes are more 
common in Gram-negative bacteria, which are 
found in higher levels in subjects with periodontitis. 
This situation may hinder successful periodontal 
treatment by tetracycline due to increased antibiotic 
resistance.
IV- Macrolide
The first described macrolide was erythromycin 
that has been available for clinical use for about 
40 years. Azithromycin and clarithromycin are 
semi-synthetic macrolides similar in structure 
to erythromycin. Azithromycin is a member 
of a new subclass of macrolide, the azalides12 
and differs from erythromycin by the addition 
of a methyl-substituted nitrogen atom into the 
lactone ring. This change produces a compound 
that is more acid stable and has a longer serum 
half-life, increased tissue penetration, and 
greater activity against gram-negative organisms 
compared with erythromycin59,172. All the macrolide 
related compounds are available for oral use and 
clarithromycin is also available as an intravenous 
infusion. erythromycin is effective against gram-
positive bacteria and spirochetes, but not against 
most gram-negative organisms. It is often used 
as an alternative to penicillin for those patients 
who are allergic to this antibiotic. All macrolides 
are well absorbed from the gastro-intestinal tract 
and diffuse readily into most tissues. erythromycin 
is inactivated in the liver, whereas clarithromycin 
is converted into an active metabolite. The major 
route of elimination for macrolides is via the bile134.
The macrolides, lincosamides and streptogramin 
B class of antibiotics target bacterial ribosomes134. 
Although there is general agreement that macrolide-
lincosamide-streptogramin antibiotics inhibit 
protein synthesis by binding to ribosomes, the 
actual mechanism has only recently been explained. 
It has been suggested that macrolide antibiotics, 
which consist of a 12- to 16-membered lactone ring 
replaced with one or more sugars, inhibit protein 
synthesis by two different mechanisms depending 
on their structure, blocking elongation of the 
nascent polypeptide by binding to the opening of 
the ribosomal exit tunnel causing a drop-off event 
leading to the accumulation of toxic peptidyl-
transfer RNA110.
Three mechanisms of resistance to macrolides 
have been described, comprising:
 a) Preventing the drug from reaching its target: 
limiting the access of macrolides to the cells (efflux 
pumps);
 b) Altering the target: altering the ribosome to 
prevent effective binding of macrolides;
 c) Inactivating the antibiotic: bacterial production 
of inactivating enzymes.
IVa- Efflux
Distinct efflux genes have been described. The 
expression of genes in the MeF family may also be 
associated with low-level macrolide resistance in the 
bacteria of the oral microbiota, encoding another 
efflux pump7,71. Efflux by an ATP-binding transporter 
encoded by msrA was found in S. aureus117. In 
gram-negative bacteria the pumps are frequently 
of the RND variety, and in gram-positive bacteria, 
both the major facilitator super family (MFS) and 
the ABC transporter super families are found79,123.
IVb- Target modiﬁcation
Target modification can be due to the acquisition 
of one of 21 erm genes. These codes for rRNA 
methylases bring about methylation of adenine 
residues in 23S rRNA, preventing the binding of 
macrolides to the 50S ribosomal subunit. The 
more common ribosomal modification however, is 
mutation of nucleotide 2058 again, which resides in 
the macrolide binding pocket of the 23S ribosomal 
RNA. In eubacteria this is invariably adenine and a 
point mutation resulting in a guanine at this position 
interferes with macrolide binding151,170.
IVc- Antibiotic modiﬁcation
There have been reports of a variety of enzymes 
of the three classes of antibiotics: macrolide-
lincosamide-streptogramin, other than methylases, 
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which inactivate the antibiotic and usually act only 
on bone. These include hydrolases, which inactivate 
streptogramin B; esterases, which inactivate 
erythromycin; transferases which inactivate either 
lincomycin or streptogramin A, and phosphorylases 
which inactivate macrolides123. Another mechanism 
by which bacteria express macrolide resistance 
includes drug inactivation by an enzyme encoded 
by mph151.
IVd. Resistance of oral species
Ioannidou, et al.64 (2001) observed macrolide 
resistance to oral α-haemolytic streptococci 
in healthy Greek children. In 200 isolates, the 
prevalence of resistance to the two drugs was 
similar; the MIC90 for erythromycin was twice that 
of the value for clarithromycin. With 53% of isolates 
being resistant, S. oralis isolates showed the highest 
prevalence of resistance to erythromycin, after S. 
salivarius and S. sanguinis, with 48% and 44% of 
isolates resistant to this drug, respectively. A study 
by Sefton133 in 1999 demonstrated the presence 
of resistant species and the changes in the oral 
flora after administration of macrolides in patients 
with periodontal disease. Resistant streptococci 
increased significantly when compared with the 
placebo group, and remained at elevated levels for 
up to 3 months after treatment133.
Macrolide resistance in oral anaerobes frequently 
occurs together with tetracycline resistance151. 
Andres, et al.4 (1998) discusses the link between 
erythromycin and tetracycline resistance and 
β-lactamase production in Gram-negative 
anaerobes, concluding that they were associated 
with conjugative elements in oral Prevotella species. 
Sanai, et al.127 (2002) investigated the antibiotic 
resistance of P. gingivalis, P. intermedia and P. 
nigrescens. The action of erythromycin resistance 
genes alone and tetracycline resistance genes 
alone was similar in all of the strains. An equal 
proportion of P. intermedia isolates carried erm(F) 
alone or tet(Q) alone (21% each, respectively). 
This has also been observed in other Prevotella 
species127. The effect on oral biofilms of a single 
tetracycline pulse demonstrated the relationship 
between tetracycline and erythromycin resistance. 
Of the isolates resistant to tetracycline, 67% were 
also resistant to erythromycin. A single pulse of 
tetracycline selected for erythromycin-resistant 
isolates, as shown by the increase in the proportion 
of such isolates in the biofilms from 5% to 28%115. 
The increasing prevalence of microorganisms 
resistant to erythromycin and the knowledge that 
erythromycin is considered the macrolide with the 
worst unwanted gastrointestinal effects have led to 
a decrease in the prescription of this drug both in 
medicine and in dentistry on the last decade10,134.
Haffajee, et al.51 (2008) observed ninety-two 
subjects with periodontitis. They were randomly 
allocated to one of four treatment groups receiving 
either SRP alone or combined with systemically 
administered azithromycin (500 mg once daily for 
3 days), metronidazole (250 mg tid for 14 days), 
or doxycycline (200 mg bid for 12 weeks). Subjects 
were clinically and microbiologically monitored at 
baseline (before therapy) and at 3, 6, and 12 months 
post-therapy. The proportion of resistant isolates 
was determined in saliva samples and in subgingival 
plaque samples at baseline and 12 months, and in 
two of these samples at time intervals of 2 weeks 
and 3 and 6 months. At the end of the study, 
the percentage of resistant isolates increased in 
plaque samples in all adjunctive treatment groups, 
peaking at the end of administration, but returned 
to pretreatment levels by 12 months.
V- Metronidazole
Metronidazole, a nitroimidazole compound, was 
discovered in the late 1950s when researchers at 
Rhone-Poulenc Research Laboratories in France 
were trying to create a synthetic product from 
a Streptomyces spp called azomycin that would 
have activity against Trichomonas vaginalis. 
Metronidazole was initially found to be effective 
against certain protozoan pathogens: T. vaginalis, 
Giardia lambliae and Entamoeba histolytica. In a 
letter to the editor published in Lancet, Shinn136 
(1962) reported on a patient with T. vaginalis and 
acute ulcerative gingivitis, who had a “double cure” 
after treatment with metronidazole for a week. This 
clinical observation led to studies that established 
metronidazole as an important antibiotic for 
anaerobic infection35. Since then, this compound has 
also played an important role in treating anaerobe 
related infection in the oral cavity84,111, abdomen38 
and female genital tract65,85, among others. 
Recently, Helicobacter pylori has been strongly 
associated with gastritis and duodenal ulcers, and 
classic regimens for eradicating this pathogen have 
included metronidazole39,44,141,147.
Metronidazole can be considered a prodrug in 
the sense that it requires metabolic activation by 
sensitive organisms. The mechanism of action is 
believed to involve 4 phases: (1) entry into the 
bacterial cell; (2) reduction of the nitro group; (3) 
cytotoxic effect of the reduced product; and (4) 
release of end products that are inactive97. The 
formation of the redox intermediate intracellular 
metabolites is believed to be the key component of 
microorganism killing by metronidazole.
The intracellular targets for these intermediates 
could be the RNA, DNA or cellular proteins of 
the organisms38. Metabolic pathways of low 
redox potential, which are linked to ferredoxin or 
flavodoxin-like electron transport components, 
reduce metronidazole with great efficacy. Such 
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pathways are characteristic of susceptible anaerobic 
protozoa and bacteria but are absent in aerobic and 
microaerophilic bacteria and also in host cells97. 
Therefore, all aerobic organisms are intrinsically 
resistant to these compounds.
Although metronidazole has been extensively 
used, acquired resistance to this drug has rarely 
been reported, especially for organisms that are 
considered classically susceptible, such as T. 
vaginalis and species of the Bacteroides fragilis 
group35,129. Decreased intracellular reduction and 
slower uptake of the drug are seen to be the main 
mechanism of resistance, but the genetic basis 
of these mechanisms is still unknown. Strains of 
T. vaginalis isolated from patients with refractory 
cases of trichomoniasis have been shown to 
contain decreased levels of ferredoxin, the protein 
that catalyzes reduction of metronidazole in these 
organisms. They also exhibit a corresponding 
reduction in the rate of ferredoxin gene transcription 
in comparison with drug-susceptible strains111. 
Resistance in H. pylori has been shown to emerge 
during antibiotic treatment43,58, and the prevalence 
of resistance can be associated with previous intake 
of metronidazole93. However the exact mechanism 
of metronidazole resistance for H. pylori is not well 
understood. Moore, et al.95 (1995) investigated the 
uptake of metronidazole by sensitive and resistant 
strains of H. pylori. Both strains displayed rapid 
uptake of metronidazole, although the resistant 
strains accumulated the drug at a slower rate 
and in a smaller amount than the sensitive strain. 
Both slower uptake and decreased intracellular 
reduction of the drug were found in a strain of B. 
fragilis resistant to metronidazole152. Moreover, in 
1978, Ingham, and co-worker63 isolated a B. fragilis 
strain (NCTC 11295) with a level of resistance to 
metronidazole from a patient with Crohn’s disease 
after a long-term metronidazole regimen. Since 
those first findings other resistant strains have 
been found in clinical specimens34; however they 
are still rare.
Four genes, nimA, nimB, nimC and nimD, have 
been found which are able to confer moderate 
to high-level metronidazole resistance53,154,155. 
They are located on either the chromosome or 
a variety of plasmids140 and are transferable by 
conjugation or by transformation. All the nim genes 
have been found in Bacteroides species and they 
likely code for a 5-nitroimidazole reductase which 
enzymatically reduces the 5-nitroimidazole to a 
5-amino derivative116.
Va- Resistance of oral species
Metronidazole seems to be effective against 
most Gram-negative anaerobic organisms found 
in the subgingival microbiota. Abu-Fanas, et 
al.3 (1991) tested the susceptibility to different 
antibiotics of 61 Gram-negative rods isolated from 
deep periodontal pockets, including P. gingivalis, 
C. gracilis and F. nucleatum. Metronidazole was 
effective against all isolates except for a few strains 
of C. gracilis. A. actinomycetemcomitans, which is 
not an obligate anaerobe, is inherently resistant to 
metronidazole77. The combination of metronidazole 
and amoxicillin has been reported to be effective 
in the treatment of A. actinomycetmcomitans-
associated periodontitis159,160. However, in an in 
vitro study, Muller, et al.96 (2002) found most 
strains of A. actinomycetemcomitans resistant to 
metronidazole while van Winkelhoff, et al.157 (2005) 
reported resistance of this bacterium to amoxicillin 
in Spanish patients.
Listgarten, et al.82 (1993) studied the pattern 
of antibiotic resistance in subgingival samples 
from patients with refractory periodontitis. 
Metronidazole resistance was recorded in 0-2% 
of anaerobic subgingival isolates, including 
Campylobacter rectus, F. nucleatum, P. intermedia 
and P. micra. Furthermore, biofilms offer bacterial 
resistance to antimicrobial therapy132,139. For this 
reason, taking into account the biofilm mode of 
growth of subgingival bacteria, Larsen, et al.76 
(2002) evaluated the susceptibility of P. gingivalis 
to metronidazole. The minimal bactericidal 
concentration (MBC) for biofilm cells was higher 
than the MBC value for planktonic cells for all 
bacterial strains. Feres, et al.36 (2002), in a study 
with 20 chronic periodontitis patients, observed 
that the most prevalent resistant species in the 
metronidazole-treated group were: A. naeslundii 
1, S. constellatus, Actinomyces naeslundii 2, S. 
mitis, S. oralis, Actinomyces odontolyticus and 
S. sanguinis. The mean percentage of resistant 
isolates increased during antibiotic administration 
and returned to baseline levels by 90 days post 
therapy. Ready, et al.114 (2003) did not find any child 
(4-5 years old) harboring metronidazole-resistant 
anaerobic bacteria. Similarly, Van Winkelhoff, 
et al.157 (2005) did not observe resistance of P. 
gingivalis strains to this antibiotic. In the same 
study, F. nucleatum was shown to be resistant 
to metronidazole. More recently, Rams, et al.112 
(2011) conducted an in vitro analysis of bacterial 
resistance to metronidazole among recovered 
putative periodontal pathogens from subjects with 
severe periodontitis. 27% of the subjects harbored 
isolates resistant to 16 mg/ml of metronidazole, 
compared to 48.7% who harbored isolates resistant 
to 4 mg/ml of spiramycin and 62.2% to 8 mg/mL 
of amoxicillin. Due to the relatively lower rates of 
bacterial resistance to metronidazole and to its high 
activity against the Gram-negative anaerobic bacilli, 
which are associated with periodontal diseases, 
this seems to be a promising drug for treating 
periodontitis. 
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FINAL ThOUghTS
The role of antibiotic prescription by the dental 
professionals in the selection of resistant bacteria 
is an area that has received relatively little 
attention151. However, the literature suggests that 
antibiotic resistance in the periodontal microbiota 
has increased in the past decade5,57. In Dentistry, 
the most commonly prescribed antibiotics are 
the β-lactam drugs, which are commonly used to 
treat several oral infections as well as to prevent 
bacterial endocarditis or post-surgery infection. It is 
important to note that some of these applications, 
such as the use of amoxicillin right after implant 
placement, are not scientifically sustained. This kind 
of usage should be avoided in order to reduce the 
odds of developing bacterial resistance.
Whereas periodontitis is an infectious disease, 
systemic antimicrobial therapy has been suggested 
to treat this disorder. However, it should be noted 
that there are several specific features related 
to the etiology of periodontitis that may have 
important implications for the use of antimicrobial 
agents in the periodontal therapy. Therefore, 
extrapolating the results of antibiotic treatment 
for other human infections to periodontics is not 
suitable and should be avoided. For instance, 
subgingival bacteria growing in biofilms are more 
resistant to antimicrobial treatment than planktonic 
cultures, which are normally used for antimicrobial 
susceptibility testing. Biofilm is a difficult therapeutic 
target139 that may demand higher antibiotics doses. 
Therefore, the strongest evidence on the use of 
antibiotics in the periodontal treatment should 
come from the in vivo studies. Fortunately, recent 
controlled clinical trials that have been conducted in 
an increasingly careful manner by different groups 
of investigators have helped to clear up several 
doubts about the proper use of systemic antibiotics 
in periodontology16,17,22,23,45,51,52,94,138. Overall these 
studies have showed that systemic antibiotics, 
especially the combination of metronidazole and 
amoxicillin are important adjuncts in the treatment 
of aggressive and chronic periodontitis. Some 
questions such as the ideal dose, duration and time 
of drug administration are still under investigation.
Finally, the dental professional should bear in 
mind that the non-specific or indiscriminate use 
of antibiotics may generate problems related to 
increase side-effects and bacterial resistance. 
However, when properly used, systemic antibiotics 
are very important tools in the treatment of 
periodontal diseases as well as of other oral 
infections.
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